Novartis to advance malaria program into PhIII in bid to fight drug resistance
Wednesday, 23 November 2022, 16:56:44
Novartis is moving an anti-malaria drug into a Phase III trial that it hopes could provide a new weapon against drug-resistant strains of the infection. The company and its Swiss non-profit partner Medicines for Malaria Venture, or MMV, announced Wednesday that they are moving forward with the treatment, which uses
— Endpoints News
Novartis” Malaria Treatment Candidate To Move Forward With Phase 3 Development Next Year
Wednesday, 23 November 2022, 16:36:55
Novartis AG (NYSE: NVS ) and Medicines for Malaria Venture (MMV) have decided to progress ganaplacide/lumefantrine- solid dispersion formulation (SDF) into Phase 3 development for the treatment of patients with acute uncomplicated malaria. Ganaplacide is a novel agent with a new mechanism of action combined with a new formulation of lumefantrine optimized for once-daily dosing. This combination has the potential not only to … Full story available on Benzinga.com
— Benzinga
Novartis, MMV to advance new malaria therapy in phase 3 trial
Wednesday, 23 November 2022, 11:25:21
Novartis (NVS) and Medicines for Malaria Venture ((MMV)) have decided to advance ganaplacide/lumefantrine- solid dispersion formulation ((SDF)) into phase 3 development to treat…
— Seeking Alpha
Immunocell Therapy Market Competitive Analysis with Growth Forecast 2022 to 2028 | Gilead Sciences, Novartis
Wednesday, 23 November 2022, 06:33:42
The Global Immunocell Therapy Market can be obtained through the market details such as growth drivers, latest developments, Immunocell Therapy market business strategies, regional study, and future market status. The report also covers information including Immunocell Therapy industry latest opportunities
— OpenPR
Novartis claims two firms are infringing its patent for multiple sclerosis drug
Monday, 21 November 2022, 18:53:40
The medicine is used in the treatment of relapsing-remitting multiple sclerosis and contains the active ingredient fingolimod
— The Irish Times
We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.
